ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, announces discovery of a highly ...

NANTES, France – June 2, 2025, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today provided clinical updates on Tedopi®, the “off-the-shelf” neo-epitope-based ...

Epitope Binning-seq streamlines epitope comparison, enabling rapid identification of antibodies with similar binding patterns, potentially advancing targeted and effective antibody-based therapies.

Dubbed “epitope editing” by the researchers, the technique works by using CRISPR to edit a single nucleotide on the CD45 epitope, the portion where a CAR-T cell would bind, on both the CAR-T ...

Therefore, identifying distinct epitope bins with functional activity can potentially assist in generating a reduced panel of epitope-diverse candidates to select from, with different modes of ...

Since the therapeutic efficacy of antibodies is closely related to their target epitopes, epitope characterization is essential for understanding antibody functionality. However, the traditional ...

Schulte et al, HOGVAX: Exploiting epitope overlaps to maximize population coverage in vaccine design with application to SARS-CoV-2, Cell Systems (2023). DOI: 10.1016/j.cels.2023.11.001 ...

3 While the majority of nonedited HSPC were killed by CAR T cells directed against the markers in in vitro assays, epitope-edited cells survived. Each line of edited cells also maintained its stemness ...

OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and Non-Small Cell Lung Cancer TEDOPaM - Phase 2 first positive results in ...

OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and ...